The Telangana State Drug Control Administration (DCA) and the Drug Controller General of India (DGCI) have given Indian Immunologicals (IIL) permission to manufacture the measles-rubella (MR) vaccine. The product, which is the result of an Indo-Vietnam partnership, has been in development for more than six years, and IIL is working with Polyvac, a center for research and production of vaccines and biologicals in Vietnam.

The measles vaccine component will be provided by Polyvac under an exclusive contract. In contrast, the rubella vaccine component will be supplied by IIL to create a combined MR vaccine, according to the Hyderabad-based company, which also announced the DCGI and DCA approvals on Monday.

According to IIL, a division of the National Dairy Development Board, this vaccine has been shown through thorough human clinical trials to be immunogenic and safe for people aged 9 months to 49 years. The UIP of India includes the measles-rubella vaccination on its list.

The Ministry of Health and Family Welfare has been conducting an MR vaccination campaign in the 9-month-to-less-than-15-year-old age group in a phased manner nationwide. India has committed to eradicating measles and controlling rubella (CRS) along with other WHO Southeast Asia region member countries.

(Source: https://www.thehindu.com/news/cities/Hyderabad/indian-immunologicals-gets-dcgi-nod-for-measles-rubella-vaccine/article66667942.ece )